This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)(Learn how and when to remove this template message)
|Founded||09 March 1908|
|Headquarters||Frankfurt am Main|
|Products||Xeomin, Mederma, Solvex|
|Revenue||€1,157 million (2014-2015) |
Number of employees
Merz Pharma GmbH & Co. KGaA is an international healthcare company specializing in over-the-counter and prescription creams, ointments and injectables in the fields of dermatology, neurology and metabolic disorders. Based in Frankfurt am Main, Germany, Merz is a leader in the field of Alzheimer's disease research and developed memantine as the first drug for the treatment of moderate to severe Alzheimer's disease. Other franchises covered by Merz are hepatology / metabolic diseases and dermatology (including Mederma scar gel). In Asia Pacific, the Merz franchise covers aesthetic dermatology (including Radiesse and Xeomin).
Merz was founded in 1908, has over 2700 employees and had 994 million euros of sales in 2013-14. The US subsidiary of Merz is Merz Pharmaceuticals LLC which was located in Greensboro, North Carolina. However, Merz has recently decided to move to Raleigh, North Carolina.
Merz Pharma is considered to be a leader in the aesthetics, dermatology and neurosciences markets and it consolidated its position by the $600 million purchase of niche aesthetics medical device maker, Ulthera.
- Company website  accessed October 27, 2016
- "Research & Development". Merz.com. Merz. Retrieved 27 June 2014.